Regeneron Pharmaceuticals (REGN) Change in Accured Expenses (2009 - 2026)

Regeneron Pharmaceuticals' Change in Accured Expenses history runs 18 years deep, the most recent figure standing at $492.7 million for Q2 2026.

• In Q2 2026, Change in Accured Expenses rose 127.68% year-over-year to $492.7 million; the TTM figure through Jun 2026 stood at $1.3 billion (up 216.1% YoY), while the FY2025 annual figure was $736.8 million, changed 0.23% from the prior year.
• Change in Accured Expenses for Q2 2026 stood at $492.7 million, up from $107.7 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $759.2 million in Q3 2025, with the low at -$250.4 million in Q1 2022.
• The 5-year median for Change in Accured Expenses is $114.8 million (2023), against an average of $140.7 million.
• The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses tumbled 621.61% in 2022, then surged 460.95% in 2023.
• Regeneron Pharmaceuticals' Change in Accured Expenses stood at $347.6 million in 2022, then slumped by 139.9% to -$138.7 million in 2023, then jumped by 262.65% to $225.6 million in 2024, then tumbled by 110.95% to -$24.7 million in 2025, then jumped by 2094.74% to $492.7 million in 2026.
• Business Quant data shows REGN's Change in Accured Expenses at $492.7 million in Q2 2026, $107.7 million in Q1 2026, and -$24.7 million in Q4 2025.